Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of BI 1467335 in patients with clinical evidence of NASH
2016-000499-83Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing BI 1467335 dose arm(s) with Placebo (2 arms). Primary endpoint: Plasma amine oxidase copper-containing 3 activity relative to baseline. Started Mar 2017; status: completed.
02
Drugs
PXS-4728A
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-000499-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000499-83.